Author

A. Majdi

Observed names: Abdelali (Ali) MAJDI, Abdelali Majdi

Institutions: Mohammed V University, National Institute of Oncology

Observed institutions: Mohammed V University, Bayer (Switzerland), National Institute of Oncology, Bayer (Germany)

OpenAlex ID: A5019133027

Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021

2024 · Nicola L. Barclay, Edward Burn, et al. · Scientific Reports · 42

Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study.

2024 · Marcia S. Brose, C. Benedikt Westphalen, et al. · Journal of Clinical Oncology · 7

Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer

2025 · Marcia S. Brose, C. Benedikt Westphalen, et al. · JCO Precision Oncology · 5

Psychosocial impact of malnutrition following radiotherapy for head and neck cancer: A retrospective study

2025 · A. Majdi, F.Z. Chraa, et al. · Clinical Nutrition ESPEN

The practice of ketogenic diet by patients followed for breast cancer during radiotherapy

2025 · R. Laraichi, S. Smiti, et al. · Clinical Nutrition ESPEN

Role of nutritional counseling in reducing unplanned hospitalizations during radiotherapy for pelvic cancers

2025 · C. Ezzouitina, A. Majdi, et al. · Clinical Nutrition ESPEN

Association between nutritional status and treatment response and survival in patients treated with chemoradiotherapy for cervical cancer: A prospective study of 120 patients

2025 · C. Ezzouitina, A. Majdi, et al. · Clinical Nutrition ESPEN

P-311 A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)

2015 · M. Ducreux, A. Falcone, et al. · Annals of Oncology

Works count: 8

Citation count: 54

H-index: 3

I10-index: 1